Everychem's solution, similar to PP405, has mixed results for hair regrowth, with some users reporting improvements and others seeing no change or worsening hair loss. Users are sharing experiences and updates to determine its effectiveness.
The conversation is about skepticism regarding hair growth results after 4 months of using finasteride and minoxidil. Many users doubt the authenticity of the progress pictures, suggesting the hair growth is too rapid to be real.
GHK-Cu is being considered for hair growth, but users report mixed results. Some use it alongside other treatments like 5AR inhibitors, making it hard to determine its effectiveness.
The post discusses a phase 2 trial for HMI-115, a hair loss treatment, in China, specifically seeking volunteers aged 18-65 with Norwood 3 vertex, 4, and 5 hair loss. The conversation includes questions about the specific recruitment criteria and how to volunteer.
A user shared their 4-month hair regrowth progress using 0.5mg dutasteride and 2.5mg minoxidil, reporting no side effects and significant improvement. The conversation includes discussions on treatment choices, dosages, and personal experiences with hair loss treatments.
The progress of Phase I of HMI-115, a potential hair loss treatment, which consists of Minoxidil, finasteride, and RU58841. The estimated completion date is June.
The user has been using a finasteride and minoxidil combo spray from Hims for four months, with positive results and no side effects. They apply four sprays nightly, targeting the crown and front of the scalp.
New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.
A user shared their 4-month progress using 1mg finasteride and minoxidil foam once a day for hair loss. Another user complimented the results and asked about their age.
GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.
The user shared progress pictures showing hair improvement over four months using 1 mg finasteride and 5 mg minoxidil daily. They reported no significant side effects and plan to reduce the minoxidil dose once satisfied with the results.
The user shared progress pictures after four months of using finasteride, minoxidil, a dermaroller, and biotin for hair loss. They discussed their treatment regimen and results.
The conversation is about hair loss treatment progress using finasteride and GHK-CU over six months. Users discuss application methods and share experiences with GHK-CU and AHK.
User shares progress after 4 months of using finasteride and dermarolling, with occasional use of coconut and rosemary oil. They aim to stop hair loss and hope for increased top density.
Hair growth can be induced without stopping DHT, as seen with Minoxidil. HMI115 may work by promoting follicle growth, not targeting the root cause of hair loss (DHT).
The conversation jokes about hair loss treatments, mentioning finasteride, minoxidil, dutasteride, microneedling, ketoconazole shampoo, and rosemary oil as if they were players in a game. Some users also discuss the use of finasteride for prostate issues and the possibility of splitting the dose.
A user shared progress pictures showing improvement from NW 6 to NW 2 after four months of treatment. They are considering using exosomes to further reverse hair miniaturization.
A 26-year-old male experienced significant hair regrowth using a 4-in-1 topical treatment from Hims, which includes minoxidil, finasteride, ketoconazole, and biotin, over four months. The user reported increased body and beard hair, skin changes, and no negative sexual side effects, while others noted the rapid and impressive results as atypical.
The user is frustrated about not hearing any updates on the HMI-115 trial for hair loss. They are questioning if there will be any updates in the future.
GHK-Cu and AHK-Cu peptides show limited success for hair loss, with skepticism about their effectiveness and concerns about misleading claims. Users report better results when combined with treatments like finasteride, dutasteride, minoxidil, and other methods.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115 release timeline is uncertain, with possible grey market availability in 2024-2025.
The conversation is about a user experiencing positive hair regrowth results after using finasteride, minoxidil spray, dermapen, and low-level light therapy (LLLT) for four months. The user recommends using a specific device for LLLT and mentions using the Hims spray for finasteride and minoxidil.
A user shared a 4-month update showing thicker and healthier hair after using finasteride and minoxidil. Advice was given on how to better track progress, especially with curly hair.
A user's progress with treating hair loss, using minoxidil, finasteride and microneedling. The user experienced impressive results after four months of treatment, and mentioned that stopping recreational drugs and losing weight helped their hair regrowth.
A man shared his 4-month progress using finasteride, minoxidil, and microneedling for hair loss treatment. He experienced positive results without side effects, and plans to continue the regimen.
The user shared a 4-month update on their hair loss treatment, using 2.5 mg OM daily, 0.5 mg Dutasteride three times a week, and a multivitamin with biotin. They provided progress pictures to show their results.
A 40-year-old user reports promising hairline improvement after 4 months of using 1mg finasteride daily and 5% minoxidil foam 2-2.5 times daily. The hairline vellus hair appears to be turning terminal.
PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.